Clinical trial
Study to Evaluate the Safety and Efficacy of Luspatercept (ACE-536) in…
NCT01749540 · Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA, Industry · Completed
Key facts
| NCT number | NCT01749540 |
|---|---|
| Title | Study to Evaluate the Safety and Efficacy of Luspatercept (ACE-536) in Participants With Beta-thalassemia (A536-04/MK-6143-002) |
| Official title | A Phase 2, Open-Label, Ascending Dose Study to Evaluate the Effects of ACE-536 in Patients With β-Thalassemia |
| Lead sponsor | Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | B-Thalassemia |
| Intervention type | Drug |
| Interventions | luspatercept |
| Enrollment | 64 |
| Start date | Feb 28, 2013 |
| Primary completion | Nov 11, 2015 |
| Completion | Nov 11, 2015 |
| First posted | Dec 13, 2012 |
| Last update posted | Jul 18, 2024 |
| Countries | Greece, Italy |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: